Mangrove Partners IM LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm purchased 247,317 shares of the medical instruments supplier’s stock, valued at approximately $47,997,000. Becton, Dickinson and Company accounts for about 3.9% of Mangrove Partners IM LLC’s holdings, making the stock its 6th largest holding.
A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after purchasing an additional 4,223,149 shares during the last quarter. State Street Corp boosted its stake in shares of Becton, Dickinson and Company by 0.8% in the 4th quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock worth $2,714,871,000 after buying an additional 116,737 shares during the last quarter. First Eagle Investment Management LLC boosted its stake in shares of Becton, Dickinson and Company by 16.5% in the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock worth $2,260,139,000 after buying an additional 1,651,592 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Becton, Dickinson and Company by 3.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier’s stock worth $1,841,083,000 after buying an additional 336,110 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Becton, Dickinson and Company by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier’s stock worth $1,331,165,000 after buying an additional 53,884 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.
Becton, Dickinson and Company Price Performance
Becton, Dickinson and Company stock opened at $145.28 on Wednesday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The business’s 50 day simple moving average is $149.64 and its 200 day simple moving average is $173.23. The company has a market cap of $40.03 billion, a price-to-earnings ratio of 36.78, a PEG ratio of 10.30 and a beta of 0.22.
Becton, Dickinson and Company Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio is presently 106.33%.
Insider Activity at Becton, Dickinson and Company
In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $151.48, for a total value of $166,628.00. Following the completion of the transaction, the executive vice president owned 14,272 shares in the company, valued at approximately $2,161,922.56. The trade was a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 4,013 shares of company stock worth $593,434. 0.40% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
BDX has been the topic of a number of research analyst reports. Argus cut their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. TD Cowen cut their target price on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research note on Monday, May 4th. The Goldman Sachs Group cut their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Bank of America cut their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Finally, Evercore boosted their target price on Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $181.00.
Check Out Our Latest Stock Report on Becton, Dickinson and Company
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Gravity Check: Houston, SpaceX Has a Valuation Problem
- Strategy’s Bitcoin Rally Has a Hidden Engine
- Okta’s AI Moment May Be Bigger Than Investors Realize
- 3 Rate-Ready Stocks for the New Fed Chair’s First Big Test
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
